圣湘生物
(688289)
| 流通市值：117.73亿 | | | 总市值：117.73亿 |
| 流通股本：5.79亿 | | | 总股本：5.79亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 475,488,325.65 | 1,458,061,552.96 | 1,032,580,636.67 | 716,957,551.18 |
| 营业收入 | 475,488,325.65 | 1,458,061,552.96 | 1,032,580,636.67 | 716,957,551.18 |
| 二、营业总成本 | 360,282,099.93 | 1,278,340,817.64 | 888,194,458.51 | 586,952,044.77 |
| 营业成本 | 110,726,245.56 | 322,054,954.12 | 232,314,189.76 | 162,995,059.19 |
| 税金及附加 | 2,842,427.76 | 12,412,479.1 | 7,536,727.57 | 4,820,402.23 |
| 销售费用 | 148,902,887.06 | 499,820,112.75 | 342,156,718.12 | 223,566,517.57 |
| 管理费用 | 58,460,314.53 | 251,654,185.67 | 176,534,426.64 | 118,798,228.11 |
| 研发费用 | 59,028,378.14 | 277,685,929.66 | 189,915,613.99 | 117,616,680.71 |
| 财务费用 | -19,678,153.12 | -85,286,843.66 | -60,263,217.57 | -40,844,843.04 |
| 其中:利息费用 | 6,099,989.74 | 18,395,334.85 | 16,803,462.33 | 11,328,290.64 |
| 其中:利息收入 | 23,197,918.99 | 97,526,509.16 | 77,740,767.52 | 51,368,184.17 |
| 加:公允价值变动收益 | 1,147,650.07 | 8,408,087.48 | 7,438,095.29 | 5,726,346.91 |
| 加:投资收益 | -13,365,546.27 | -28,844,174.11 | -28,614,110 | -34,229,360.64 |
| 资产处置收益 | 258,365.08 | -2,362,321.35 | -1,899,035.23 | 216,607.24 |
| 资产减值损失(新) | 895,902.96 | 43,832,062.69 | 15,624,281.83 | 9,851,981.9 |
| 信用减值损失(新) | -7,601,842.94 | -14,804,925.24 | -1,781,600.92 | 4,230,394.08 |
| 其他收益 | 4,552,561.67 | 91,827,182.93 | 73,490,839.59 | 58,610,212.06 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 101,093,316.29 | 277,776,647.72 | 208,644,648.72 | 174,411,687.96 |
| 加:营业外收入 | 3,301,308.45 | 1,768,960.98 | 383,788.53 | 199,834.37 |
| 减:营业外支出 | 5,247,099.16 | 18,934,570.02 | 8,822,619.89 | 6,313,461.5 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 99,147,525.58 | 260,611,038.68 | 200,205,817.36 | 168,298,060.83 |
| 减:所得税费用 | 18,513,607.11 | 34,338,337.95 | 37,128,823.35 | 32,646,558.87 |
| 六、净利润 | 80,633,918.47 | 226,272,700.73 | 163,076,994.01 | 135,651,501.96 |
| 持续经营净利润 | 80,633,918.47 | 226,272,700.73 | 163,076,994.01 | 135,651,501.96 |
| 归属于母公司股东的净利润 | 91,735,483.67 | 275,596,143.87 | 195,427,005.64 | 156,705,803.45 |
| 少数股东损益 | -11,101,565.2 | -49,323,443.14 | -32,350,011.63 | -21,054,301.49 |
| (一)基本每股收益 | 0.16 | 0.47 | 0.34 | 0.27 |
| (二)稀释每股收益 | 0.16 | 0.47 | 0.33 | 0.26 |
| 八、其他综合收益 | 161,778.27 | -4,533,779.91 | -85,769,939.35 | -80,468,805.84 |
| 归属于母公司股东的其他综合收益 | 161,778.27 | -4,253,464.13 | -9,443,183.89 | -4,142,050.38 |
| 九、综合收益总额 | 80,795,696.74 | 221,738,920.82 | 77,307,054.66 | 55,182,696.13 |
| 归属于母公司股东的综合收益总额 | 91,897,261.94 | 271,342,679.74 | 185,983,821.75 | 152,563,753.08 |
| 归属于少数股东的综合收益总额 | -11,101,565.2 | -49,603,758.92 | -108,676,767.09 | -97,381,056.95 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-24 | 2024-08-19 |
| 审计意见(境内) | | 标准无保留意见 | | |